- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05003375
Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS) (PREFIMS)
Physiological Responses in Experimentally Induced Cognitive Fatigue in People With Multiple Sclerosis (MS): a Feasibility Study
The current study will add to the current knowledge by combining several electrophysiological techniques to examine the relationship between physiological responses and cognitive fatigue and daily activity performance in a stress- and fatigue-inducing protocol.
The aims of this study are: 1) to evaluate the feasibility and usability of assessing physiological responses in an experimental set-up and 2) to investigate the association between physiological outcomes, experimentally induced stress and cognitive fatigue in people with multiple sclerosis (MS) and healthy controls.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In an experimental set-up participants (20 people with MS and 20 healthy controls) will perform a high-challenging cognitive protocol to provoke stress and (cognitive) fatigue.
Physiological responses (heart rate variability, skin conductance, body temperature) and brain activity (EEG) will be measured while resting (resting baseline), while speaking as normal (speaking baseline), during protocol performance and following the protocol (post-protocol).
Demographic and clinical characteristics, as well as levels of perceived fatigue, stress, pain, daily activity performance, quality of life and anxiety and depression will be assessed using medical records and questionnaires.
Feasibility and usability will be assessed in participants and researcher(s) by standardized questionnaires.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Daphne Kos, PhD
- Phone Number: +32496-107849
- Email: daphne.kos@kuleuven.be
Study Contact Backup
- Name: Niels Peeters, MSc
- Phone Number: +32474296463
- Email: daphne.kos@kuleuven.be
Study Locations
-
-
-
Leuven, Belgium, 3000
- Recruiting
- KU Leuven, Department of Rehabilitation Sciences
-
Contact:
- Daphne Kos, PhD
- Email: daphne.kos@kuleuven.be
-
Contact:
- Niels Peeters, MSc
- Email: niels.peeters@kuleuven.be
-
Melsbroek, Belgium
- Recruiting
- National Multiple Sclerosis Center
-
Contact:
- Sofie Ferdinand, Ba
- Phone Number: +3225978690
- Email: sofie.ferdinand@mscenter.be
-
Contact:
- Mieke D'hooge, MSc
- Email: mieke.dhooge@mscenter.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- diagnosis MS, Relapsing Remitting (RR) type (MS group)
- Expanded Disability Status Scale (EDSS) <6 (MS group)
- Dutch speaking
- normal or corrected vision
- feasible use of computer
Exclusion Criteria:
- relapse < 3 months (MS group)
- pregnancy
- relevant comorbidity (thyroid disease, diabetes, other neurological disorders, metabolic diseases, neuro-endocrine tumor(s)
- severe cognitive disability
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Multiple Sclerosis (MS)
People with MS diagnosis, aged 18-55 years, Relapsing Remitting type, EDSS < 6.0, normal vision (if necessary corrected), Dutch speaking.
|
Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes). This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT*-NBacktask**, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2. During all these measurements, the participant will sit at a table with a computer on which the tests are performed. *SDMT: Symbol Digit Modalities Test: see description in outcome measures **N-Back Task: see description in outcome measures |
Healthy Controls (HC)
Healthy controls without relevant health conditions (diabetes, thyroid diseases, neurological disorders), non-pregnant, aged 18-55 years, normal vision (if necessary corrected), Dutch speaking.
|
Baseline measurement is done in two parts: 1) resting for five minutes (no talking, no movement) and 2) speaking at normal pace (2 minutes). This is immediately followed by a measurement of the physiological response variables during the testing, in which the following protocol is performed in the order presented: 1) SDMT-NBack task-SDMT*-NBacktask**, 2) NBack task-SDMT-NBack task-SDMT. Participants will run either sequence to check for effects of the previous testing. During the conduct of the study, it will be ensured that half of the participants in each group followed Sequence 1 and the other half of the group followed Sequence 2. During all these measurements, the participant will sit at a table with a computer on which the tests are performed. *SDMT: Symbol Digit Modalities Test: see description in outcome measures **N-Back Task: see description in outcome measures |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in heart rate variability (time-domain)
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
ECG monitoring will be done using the MindMedia NEXUS-10MKII.-
Heart Rate Variability will be studied in a time- and frequency domain.
For the time-domain following measures are studied: 1) the average normal-normal interval; 2) the standard deviation of normal-normal (SDNN); 3) the Root Mean Square of Successive Differences (RMSSD); 4) the percentage of adjacent normal-normal intervals with differences of more than 50miliseconds.
(PNN50).
|
immediately post protocol (approx. 2 hours after baseline)
|
Change in heart rate variability (frequency-domain)
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
ECG monitoring will be done using the MindMedia NEXUS-10MKII.-
Heart Rate Variability will be studied in a time- and frequency domain.
For the frequency domain, the changes in the high frequency (HF) and low frequency (LF) will be studied and analysed.
|
immediately post protocol (approx. 2 hours after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visual Analogue Scale (VAS) Momentary fatigue
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
Momentary fatigue experienced following the protocol using Visual Analogue Scale (VAS) (minimum 0- maximum 10), higher scores indicate higher fatigue.
|
immediately post protocol (approx. 2 hours after baseline)
|
Change in Visual Analogue Scale (VAS) Momentary pain
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
Momentary pain experienced following the protocol using Visual Analogue Scale (minimum 0- maximum 10), higher scores indicate higher pain.
|
immediately post protocol (approx. 2 hours after baseline)
|
Usefulness, Satisfaction, and ease of use Questionnaire (USE)
Time Frame: post protocol (approx. 2 hours after baseline)
|
The USE is a self-report questionnaire in which 30 items in four dimensions (usefulness, ease of use, ease of learning and satisfaction) are answered on a 7-point Likert scale (1 = disagree, 7 = fully agree) and one not -answer option. Higher scores indicate higher satisfaction and usefulness. |
post protocol (approx. 2 hours after baseline)
|
NASA Task Load Index (NASA-TLX)
Time Frame: post protocol (approx. 2 hours after baseline)
|
The NASA-TLX is a self-report questionnaire that measures perceived work-related stress using six dimensions with a focus on mental stress: mental, physical and time-related stress, frustration and execution. The dimensions are assessed on the basis of a semantic differential scale (0-10). The six individual scores are converted to a global score by means of a "paired comparison task" in which "comparison cards" are used prior to the assessment. Higher scores indicate higher task load. |
post protocol (approx. 2 hours after baseline)
|
Galvanic Skin Response (GSR)
Time Frame: baseline
|
|
baseline
|
Galvanic Skin Response (GSR)
Time Frame: during protocol (approx. 1 hour after baseline)
|
|
during protocol (approx. 1 hour after baseline)
|
Galvanic Skin Response (GSR)
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
|
immediately post protocol (approx. 2 hours after baseline)
|
Brain activity
Time Frame: baseline
|
• Electroencephalography (EEG):
EEG measures: - The impact of the cognitive fatigue and stress inducing protocol on alpha, beta, delta, and there frequency bands will be studied. |
baseline
|
Brain activity
Time Frame: during protocol (approx. 1 hour after baseline)
|
• Electroencephalography (EEG):
EEG measures: - The impact of the cognitive fatigue and stress inducing protocol on alpha, beta, delta, and there frequency bands will be studied. |
during protocol (approx. 1 hour after baseline)
|
Brain activity
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
• Electroencephalography (EEG):
EEG measures: - The impact of the cognitive fatigue and stress inducing protocol on alpha, beta, delta, and there frequency bands will be studied. |
immediately post protocol (approx. 2 hours after baseline)
|
Respiration
Time Frame: baseline
|
Respiration set up:
Respiration measures:
|
baseline
|
Respiration
Time Frame: during protocol (approx. 1 hour after baseline)
|
Respiration set up:
Respiration measures:
|
during protocol (approx. 1 hour after baseline)
|
Respiration
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
Respiration set up:
Respiration measures:
|
immediately post protocol (approx. 2 hours after baseline)
|
Decline in Symbol Digit Modalities Test
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
The Symbol Digit Modalities Test (SDMT) Performance
Scores
|
immediately post protocol (approx. 2 hours after baseline)
|
Decline in N-Back Task
Time Frame: immediately post protocol (approx. 2 hours after baseline)
|
The N-Back Task (NBT) Performance:
Scores:
|
immediately post protocol (approx. 2 hours after baseline)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Fatigue Impact Scale (MFIS)
Time Frame: baseline
|
The MFIS is a self-report questionnaire used to measure the perceived impact of fatigue on physical, cognitive and psychosocial functioning.
The participant answers 21 items on the basis of a 5-point Likert scale (0 = never; 5 = almost always).
A higher score on the subscales (physical dimension: 0-36; cognitive dimension: 0-40; psychosocial functioning: 0-8) or in the total score represents a higher degree of fatigue.
|
baseline
|
Perceived Stress Scale (PSS)
Time Frame: baseline
|
Questionnaire on perceived stress in daily life (14 items) The Perceived Stress Scale (PSS) is a self-report questionnaire to measure the perceived stress.
In 14 items perceived stress is judged by taking into account the previous month's experiences.. Scoring is done using a 5-point Likert scale (0 = never; 4 = very often), with a maximum score (56) representing a higher degree of perceived stress.
|
baseline
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: baseline
|
Self-report questionnaire of depression and anxiety (14 items) The HADS is aimed at assessing anxiety and depression in a non-psychiatric setting, without questioning physical complaints such as fatigue.The HADS is a self-report questionnaire of 14 items that are answered on the basis of an ordinal scale with four answer options (0-3).
Depression and anxiety subscale scores range from 0-21, with higher scores indicating increased depression or anxiety, respectively.
|
baseline
|
Life Balance Inventory (LBI)
Time Frame: baseline
|
LBI is a self-report assessment instrument containing 53 activities and on a dichotomous scale of yes/no, people have to answer, whether or not they do the activity or want to do the activity. For each item scored 'yes', participants have to rate their satisfaction with the amount of time they have spent doing that activity in the past month compared to the amount of time they wanted to do the activity. The possible answers are: "always less than I want (1), sometimes less than I want (2), about right for me (3), sometimes more than I want (2), always more than I want (1)". The LBI contains four subscales: (1) Health subscale (ex. Relaxing, getting regular exercise, …), (2) Relationship subscale (ex. Doing things with friends, partner, …), (3) Identity subscale (ex. Taking care of your appearance, participating in religious events, …), (4) Challenge/interest subscale (ex. Working for pay, making music, …). Higher scores reflect better life balance. |
baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daphne Kos, PhD, KU Leuven
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S63552
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on High-challenging cognitive protocol to provoke stress and (cognitive) fatigue
-
Stanford UniversityNot yet recruitingChronic Pain | Sedentary TimeUnited States
-
University of KonstanzCentre for Psychiatry Reichenau, GermanyCompleted
-
James B. Wetmore, MDCompletedEnd-Stage Renal DiseaseUnited States